Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Pharmaceuticals · CIK 0000059478
$1306.69
+2.83% · delayed ~15 min
Last price from Oct 22, 2026
$1.24T market value
From ELI LILLY & Co's FY2025 10-K, filed Feb 12, 2026 · read the filing
ELI LILLY & develops and makes medicines. It took in $65.18B last year, which makes it a very large company. Of every dollar it sells, about 32 cents is left as profit.
The financial picture is led by profitability, growth and debt, with accounting worth watching.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Financial health
Strong finances across the board.
From ELI LILLY & Co's FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Revenue
$45.04B → $65.18B
Gross profit
$36.63B → $54.13B
Profit
$10.59B → $20.64B
Profit margin
23.5% → 31.7%
Measured against FY2024, from the 10-K filed Feb 12, 2026
Improved: +44.7%
$45.04B to $65.18BCritical
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
How the latest move compares (quote delayed ~15 min), and what was published around it
LLY rose 2.83% on the latest quote. The average Health Care company tracked here moved +1.59%, and the S&P 500 −1.04%. That is 1.2 points above its sector and 3.9 points above the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
Opinions from 36 analysts covering this company, as of . Their views, not this site's.
Of 36 analysts publishing on this company, 11 say strong buy, 20 say buy, 4 say hold and 1 say sell. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 32 cents of every dollar of sales as profit, earning $20.64B last year.
Yes, quickly. Sales grew 44.7% last year.
No. At its current cash flow it could clear its debt in about 2.1 years. For every $1 it owes, it owns $1.31 in assets.
Core operating and valuation reference metrics
Whether the dividend is covered by what the business actually earns
It pays out 26 cents of every dollar of profit and keeps the rest, which leaves the payment comfortably covered. It paid out 32% of the cash its operations generated. It has paid in each of the last 12 years.
GoodNext payment expected around , projected from how regularly it has paid before rather than from a date the company has announced.
Figures from the FY2025 annual filing
Last year it earned $20.64B and generated $16.81B of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 12, 2026Filing for FY2025 | FY202410-K · Feb 12, 2026Filing for FY2024 | FY202310-K · Feb 12, 2026Filing for FY2023 | FY202210-K · Feb 21, 2024Filing for FY2022 | FY202110-K · Feb 21, 2024Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B | +44.7% |
| Cost of revenue | $11.05B | $8.42B | $7.08B | $6.63B | $7.31B | +31.3% |
| Gross profit | $54.13B† | $36.63B† | $27.04B† | $21.91B† | $21.01B† | +47.8% |
| Gross marginGross profit ÷ revenueWhat is this? | 83.0% | 81.3% | 79.2% | 76.8% | 74.2% | +1.7 pts |
| Selling, general and administrative | $11.09B | $8.59B | $7.40B | $6.44B | $6.43B | +29.1% |
| Interest expense | $895.0M | $781.0M | $485.9M | $331.6M | $339.8M | +14.6% |
| Income before tax | $25.73B | $12.68B | $6.55B | $6.81B | $6.16B | +102.9% |
| Net income | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B | +94.9% |
| Net marginNet income ÷ revenueWhat is this? | 31.7% | 23.5% | 15.4% | 21.9% | 19.7% | +8.2 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $21.77 | $11.15 | $5.51 | $6.56 | $5.82 | +95.3% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| LLYELI LILLY & Co · this page | 9.0/10 | 7/9 |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Was granted or awarded shares — 10 shares at $1.2K ($12.4K)
Holds 55,848 shares after this filing.
Was granted or awarded shares — 8 shares at $1.2K ($9.9K)
Holds 75,544 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Quarterly report for Q2 FY2026
Revenue +47.7% · Profit margin −5.5 pts · Gross profit +50.3% — against Q2 FY2026
Read the filingPublished results
Read the filingWrite down why you are following ELI LILLY & Co, what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 158 subsidiaries named in its 10-K, incorporated across 58 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from LLY's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 12, 2026), reported under the US GAAP taxonomy. View the source filing. Total liabilities were not tagged directly and were calculated as assets minus equity.
4 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. All four had enough reported figures. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 9.0 | 7/9 | 10-K, filed Feb 12, 2026 |
| FY2024 | 8.0 | 7/9 | 10-K, filed Feb 19, 2025 |
| FY2023 | 7.0 | 5/9 | 10-K, filed Feb 21, 2024 |
| FY2022 | 9.0 | 7/9 | 10-K, filed Feb 22, 2023 |
| FY2021 | 10.0 | 6/9 | 10-K, filed Feb 23, 2022 |
| FY2020 | 9.0 | 5/9 | 10-K, filed Feb 17, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
7 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
10.53
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-1.85
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: +47.8%
$36.63B to $54.13BCritical
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +94.9%
$10.59B to $20.64BCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +8.2 pts
23.5% to 31.7%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: +95.3%
$11.15 to $21.77Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: +43.3%
$28.53B to $40.87BCritical
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Improved: +122.4%
$3.27B to $7.27BCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Changed: +15.0%
$4.68B to $5.38BSignificant
Why it matters: Cash handed to shareholders. A rise can be a higher dividend or simply more shares, and a cut is a decision the company explains in its own filing — neither is rated here.
Improved: +1.7 pts
81.3% to 83.0%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Q2 FY2026 against Q2 FY2026, from the 10-Q filed Aug 5, 2026 — read it.
Improved: +47.7%
$15.56B to $22.97BCritical
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +50.3%
$13.11B to $19.71BCritical
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Deteriorated: +40.0%
$34.18B to $47.86BCritical
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Improved: +165.1%
$3.38B to $8.95BCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +25.3%
$5.66B to $7.09BSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: −5.5 pts
36.4% to 30.9%Significant
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: +26.1%
$6.30 to $7.95Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +1.5 pts
84.3% to 85.8%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Aug 5, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Improved: +69.4%
$5.28B to $8.95BCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +16.0%
$19.80B to $22.97BSignificant
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +21.5%
$16.22B to $19.71BSignificant
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +3.8 pts
81.9% to 85.8%Significant
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Deteriorated: −6.5 pts
37.4% to 30.9%Significant
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: +21.6%
$39.37B to $47.86BSignificant
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
1 other measure barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 0.7% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 48.1x — a high multiple relative to the current trailing profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
| 44.7% |
| 31.7% |
| 60.03x |
| 3.24x |
| JNJJOHNSON & JOHNSON | 9.0/10 | 4/9 | 6.0% | 28.5% | 24.04x | 1.44x |
|---|
| MRKMerck & Co., Inc. | 9.0/10 | 5/9 | 1.3% | 28.1% | 20.38x | 1.60x |
|---|
| PFEPFIZER INC | 7.0/10 | 6/9 | -1.6% | 12.4% | 22.19x | 1.40x |
|---|
| BMYBRISTOL MYERS SQUIBB CO | 8.0/10 | 9/9 | -0.2% | 14.6% | 18.12x | 3.87x |
|---|
| ZTSZoetis Inc. | 9.0/10 | 7/9 | 2.3% | 28.2% | 13.04x | 3.64x |
|---|
| VTRSViatris Inc | 4.0/10 | 5/9 | -3.0% | -24.7% | — | 1.53x |
|---|
| Median of peers | 8.5/10 | — | 0.5% | 21.4% | 20.38x | 1.56x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Was granted or awarded shares — 13 shares at $1.2K ($15.9K)
Holds 16,970 shares after this filing.
Was granted or awarded shares — 4 shares at $1.2K ($5.0K)
Holds 3,016 shares after this filing.
Was granted or awarded shares — 9 shares at $1.2K ($9.9K)
Holds 75,536 shares after this filing.
Was granted or awarded shares — 14 shares at $1.2K ($15.9K)
Holds 16,957 shares after this filing.
Was granted or awarded shares — 4 shares at $1.2K ($5.0K)
Holds 3,012 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 305,000 shares ($368.7M) on or after .
Shares originally obtained via Gift.
Filed notice to sell 300,000 shares ($347.2M) on or after .
Shares originally obtained via Gift.
Filed notice to sell 6,500 shares ($7.6M) on or after .
Shares originally obtained via Stock Bonus.
Filed notice to sell 2,000 shares ($2.4M) on or after .
Shares originally obtained via Restricted Stock Units and Performance Stock Units.
Filed notice to sell 10,000 shares ($11.9M) on or after .
Shares originally obtained via RSU/A Award.
Filed notice to sell 310,000 shares ($372.0M) on or after .
Shares originally obtained via Gift.
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Reported another event
Held a shareholder vote
Read the filingQuarterly report for Q1 FY2026
Revenue +55.5% · Profit margin +15.7 pts · Gross profit +54.4% — against Q1 FY2026
Read the filingPublished results
Read the filingProxy statement for a shareholder meeting
Read the filingAnnual report for FY2025
Revenue +44.7% · Profit margin +8.2 pts · Gross profit +47.8% — against FY2024
Read the filingPublished results
Read the filingHad a director or senior officer leave or join
Read the filingQuarterly report for Q3 FY2025
Revenue +53.9% · Profit margin +23.2 pts · Gross profit +57.4% — against Q3 FY2024
Read the filingPublished results
Read the filingReported another event
Read the filingQuarterly report for Q2 FY2026
Revenue +37.6% · Profit margin +10.1 pts · Gross profit +43.6% — against Q2 FY2024
Read the filingPublished results
Read the filingHeld a shareholder vote
Read the filingQuarterly report for Q1 FY2026
Revenue +45.2% · Profit margin −3.9 pts · Gross profit +48.1% — against Q1 FY2024
Read the filingPublished results
Read the filingProxy statement for a shareholder meeting
Read the filingAnnual report for FY2024
Revenue +32.0% · Profit margin +8.2 pts · Profit +102.1% — against FY2023
Read the filingThe first 40 of 158. The rest are in the exhibit.
Source: Exhibit 21 of the 10-K filed 2026-02-12. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?
Yahoo Finance ·
What Does Eli Lilly (LLY) Mean To Signal With Its $5 Billion Richmond Build?
Yahoo Finance ·
UBS portfolio manager: S&P 500 could hit 9,500 by June 2027 on AI, longevity, energy boom
Yahoo Finance ·
Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020
Yahoo Finance ·
Earnings Preview: Eli Lilly (LLY) Q3 Earnings Expected to Decline
Yahoo Finance ·
Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?
Yahoo Finance ·
Eli Lilly (LLY) Grew Revenue 48% While Prices Fell, Can Volume Keep Winning?
Yahoo Finance ·
Investors are punishing Big Tech's biggest spenders. Meta is the latest casualty.
Yahoo Finance ·
Foghorn Therapeutics (FHTX) Stock Fair Value Moves Lower After Pipeline And Lilly Reset
Yahoo Finance ·
Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline Advances
Yahoo Finance ·
NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains?
Yahoo Finance ·
Was There Any Sign Merck Stock Would Run?
Yahoo Finance ·
Primary sources and further research